miRNA Logic Gates for Conditional Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current technologies lack the ability to express therapeutic microRNA (miRNA) agents in mammalian cells according to specific miRNA signatures without using exogenous proteins, which can trigger harmful immune responses.
Innovation Solution
Development of miRNA-based logic gates that utilize engineered RNA carriers with nuclear export or import signals, target sites for specific miRNAs, and pre-miRNA sequences, allowing conditional expression of therapeutic miRNAs based on cellular miRNA signatures without exogenous proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If exogenous proteins are used to control therapeutic miRNA expression, then conditional expression can be achieved, but immune responses are triggered
Solution Approach 1:
The patent extracts and removes the harmful exogenous protein components from the system, replacing them with endogenous miRNA-based regulatory mechanisms. The logic gate system uses solely RNA elements (miRNA target sites, pre-miRNA sequences, and nuclear localization signals) that are naturally processed by cellular machinery, eliminating the immune-triggering proteins while preserving conditional expression control.
Solution Approach 2:
The patent introduces miRNA-based logic gates as intermediary elements that mediate between the therapeutic miRNA and the cellular environment. These logic gates use endogenous miRNAs as inputs and control the expression of therapeutic miRNAs as outputs, serving as a safe intermediary mechanism that avoids direct protein-mediated control and its associated immune risks.
2Productivity
If therapeutic miRNA is delivered systemically, then broad coverage is achieved, but off-target effects increase
Solution Approach 1:
The patent implements feedback control through miRNA-based logic gates that sense the cellular miRNA environment and adjust therapeutic miRNA expression accordingly. The logic gates use endogenous miRNAs as input signals and modulate therapeutic miRNA production based on the detected miRNA signature, creating a feedback mechanism that ensures therapy is activated only in cells with the correct molecular profile, thereby preventing off-target effects while maintaining systemic delivery.
3Object-affected harmful factors
If miRNA-based logic gates are used without exogenous proteins, then immune safety is improved, but device complexity increases
Solution Approach 1:
The patent designs the miRNA-based logic gates to be self-sufficient and self-regulating systems that utilize the cell's own machinery for processing and regulation. The logic gates contain all necessary elements (nuclear localization signals, miRNA target sites, pre-miRNA sequences) within their RNA structure, allowing them to autonomously sense miRNA signatures and control therapeutic expression without requiring external protein factors, thereby achieving safety while managing complexity through self-service design.
Data Source
AI summary
The present disclosure, at least in part, relates to a miRNA based logic gate that comprises an engineered RNA carrier that comprises an nuclear export signal, a target site for a first miRNA and a pre-miRNA sequence for a second miRNA. Also provided by the disclosure are recombinant viruses (e.g., recombinant adeno-associated viruses (rAAV)) for delivery of the miRNA based logic gates.